Castle Biosciences Inc
(NAS:CSTL)
$
23.58
-0.9 (-3.68%)
Market Cap: 650.98 Mil
Enterprise Value: 454.21 Mil
PE Ratio: 0
PB Ratio: 1.62
GF Score: 79/100 Castle Biosciences Inc at Canaccord Genuity Growth Conference Transcript
Aug 10, 2022 / 05:00PM GMT
Release Date Price:
$34.32
(+12.01%)
Kyle Alexander Mikson
Canaccord Genuity Corp., Research Division - Analyst
Hi, everyone. Welcome to the Canaccord Genuity 42nd Annual Global Growth Conference. I'm Kyle Mikson. I cover Life Science Tools and Diagnostics at Canaccord, and I'm pleased to present to you the management team from Castle Biosciences here with us today. We have Derek Maetzold, CEO; and then Frank Stokes, CFO. Thanks, Derek, Frank, for joining us today.
Derek J. Maetzold
Castle Biosciences, Inc. - Founder, CEO, President & Director
Thank you, Kyle.
Kyle Alexander Mikson
Canaccord Genuity Corp., Research Division - Analyst
And just as background, Castle provides a leading class of dermatologic cancer tests as well as now GI cancer tests, prognostic tests as well as mental health tests, too. So we're going to cover all that today. Looking forward to it.
Questions & Answers
Kyle Alexander Mikson
Canaccord Genuity Corp., Research Division - Analyst
So maybe just on the second
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot